ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Avenue Therapeutics Receives Complete Response Letter from FDA for IV Tramadol
October 16, 2020Avenue Therapeutics has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for IV tramadol. -
Avenue Therapeutics receives complete response letter from the FDA for IV Tramadol
October 14, 2020The CRL stated that IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. -
InvaGen to acquire Avenue Therapeutics for $215m
November 14, 2018InvaGen Pharmaceuticals, a unit of India-based Cipla, has signed definitive agreements to buy US-based specialty pharmaceutical firm Avenue Therapeutics for a total consideration of $215m.
Pharma Sources Insight January 2025
